Pharmaceutical care: (9) Coronary heart disease

Pharmaceutical Journal

Volumn 265, Issue 7108, 2000, Pages 194-205

  McGlynn, S ^a   Reid, F ^a   McAnaw, J ^a   Chinwong, S ^a   Hudson, S ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA PECTORIS; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SYMPTOMATOLOGY; UNITED KINGDOM;

EID: 0034609139     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
2. Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991
3. Secondary prevention in acute myocardial infarction
4. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study
5. Coronary and cardiovascular risk estimation for primary prevention: Validation of a new Sheffield table in the 1995 Scottish health survey population
6. The prospective ransomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus
7. Nicotine replacement therapy for smoking cessation (Cochrane Review)
8. Attributes of successful smoking cessation interventions in medical practice; a meta analysis of 39 controlled trials
9. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects
10. Cardiac rehabilitation
11. Joint British recommendations on prevention of coronary heart disease in clinical practice
12. Body weight: Implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men
13. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range
14. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia
15. Joint British recommendations on prevention of coronary heart disease in clinical practice: Summary
16. British Hypertension Society guidelines for hypertension management 1999: Summary
17. Estimating cardiovascular risk for primary prevention: Outstanding questions for primary care
18. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
20. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
21. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
22. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
23. Lowdose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial
24. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk-patients
25. Coronary heart disease: Epidemiology of smoking and intervention studies of smoking
26. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men
27. The risk of myocardial infarction after quitting smoking in men under 55 years of age
28. Decline in the risk of myocardial infarction among women who stop smoking
29. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction
30. Changes in diet in Finland from 1972 to 1992: Impact on coronary heart disease risk
31. Plant sterol and stanol margarines and health
32. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial
33. Comparison of the prediction, by 27 different factors, of coronary heart disease and death in men and women of a Scottish heart health study: Cohort study
34. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men
35. Changes in physical activity, mortality, and incidence of coronary heart disease in older men
36. Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors
37. Review of moderate alcohol consumption and reduced risk of coronary heart disease: Is the effect due to beer, wine, or spirits
38. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
39. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
40. Final report on the aspirin component of the ongoing Physicians' Health Study
41. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction; ISIS-2
42. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
43. Prevention of coronary heart disease with pravastatin in men with hypercholestrolemia
44. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of APCAPS/TexCAPS
45. Indications for ACE inhibitors in the early treatment of acute myorcardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials
46. ISIS-4; a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
47. GISSI-3: Effects of lisinopri and transdermal glyceryl trinitrate singly and together on six-week mortality and ventrieular function after acute myocardial infarction
48. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
49. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
50. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
51. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II
52. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction
53. Six year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction
54. Beta blockade during and after myocardial infarction: An overview of the randomized trials
55. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II)
56. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials
57. Preventing recurrent coronary heart disease - We need to attend more to implementing evidence based practice
58. The physician and pharmacist team. An effective approach to cholesterol reduction
59. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed care environment (the Rocky Mountain, Kaiser Permanente experience)
60. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting
61. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension
62. Lessons from experienced guideline implementers, attend to many factors and use multiple strategies
63. Pharmacist counseling and outcomes of smoking cessation
64. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting
65. Health checks and coronary risk: Further evidence from a randomised controlled trial
66. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice
67. Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): Randomised controlled trial
68. Managing established coronary heart disease
69. Secondary prevention in coronary heart disease: A randomised trial of nurse led clinics in primary care
70. Determination of who may derive most benefit from aspirin in primary prevention: Subgroup results from a randomised controlled trial